A class action lawsuit has been filed against pharmaceutical powerhouse Sanofi-Aventis alleging that the company hid data concerning adverse events associated with their obesity medication Zimulti. The French company allegedly concealed data showing Zimulti’s propensity to cause depression. Zimulti has also been shown to increase suicidal ideation and action in some cases.
In June the FDA unanimously decided that Zimulti could not be recommended for approval in the U.S.; however, the drug can be purchased through online pharmacies based in other countries.
In a statement, the law firm said FDA scientists provided an analysis of 13 studies which showed that 26 pct of patients taking the recommended dose of Zimulti had psychiatric side effects, as compared to 14 pct of those patients who received a placebo.
Additionally, studies showed that the drug also doubled cases of anxiety, depression, and other mood disorders when compared to placebo.
These are very serious allegations and if they can be substantianted Sanofi-Aventis could be in very hot water.
For more information on this subject, please refer to the section on Defective and Dangerous Products.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.